Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis : A Living Systematic Review and Network Meta-analysis for the American College of Physicians

CONCLUSION: Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab, followed by alendronate, reduce clinical fractures in postmenopausal females with osteoporosis. Abaloparatide and teriparatide increased WAEs; longer duration bisphosphonate use may increase AFF and ONJ risk though these events were rare.PRIMARY FUNDING SOURCE: American College of Physicians. (PROSPERO: CRD42021236220).PMID:36592455 | DOI:10.7326/M22-0684

Source: Annals of Internal Medicine - January 2, 2023 Category: Internal Medicine Authors: Chelsea Ayers Devan Kansagara Brittany Lazur Rongwei Fu Amy Kwon Curtis Harrod Source Type: research